ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "race/ethnicity"

  • Abstract Number: 0492 • ACR Convergence 2021

    Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus

    Mia Chandler1, Leah Santacroce2, Karen Costenbader3, Rishi Desai4, Seoyoung Kim2 and Candace Feldman2, 1Boston Children's Hospital, Brookline, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Belmont, MA, 4Brigham and Women's Hospital/Harvard Medical School, Boston, MA

    Background/Purpose: Glucocorticoids (GCs) are an integral part of systemic lupus erythematosus (SLE) treatment. Long-term use of GCs is associated with adverse effects. This study evaluated…
  • Abstract Number: 1611 • ACR Convergence 2021

    A Population-Based Evaluation of Telemedicine Use and Satisfaction in SLE Patients During the COVID-19 Pandemic in Atlanta, Georgia

    Sarah Simmons1, Cristina Drenkard2, Gaobin Bao2, Charmayne Dunlop-Thomas2, Kim Schofield2 and S Sam Lim3, 1Duke University, Durham, NC, 2Emory University, Atlanta, GA, 3Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA

    Background/Purpose: The COVID-19 pandemic resulted in the shift from in-person physician appointments to the development and proliferation of the use of telemedicine in an attempt…
  • Abstract Number: 0594 • ACR Convergence 2021

    The Burden of Systemic Lupus in Five Distinct Racial and Ethnic Groups in Israel: A Population-based Study

    Titilola Falasinnu1, Nada Rizk1, Becca Feldman2, Devy Zisman3, Michael Leshchinsky2, Gabriella Lawrence2, Yashaar Chaichian4 and Julia Simard1, 1Stanford School of Medicine, Stanford, CA, 2Clalit Research Institute, Clalit Health Services, Ramat Gan, Israel, 3Carmel Medical Center, Haifa, Israel, 4Stanford University, Los Gatos, CA

    Background/Purpose: Misclassification of race and ethnicity in data can impact how disparities in prevalence, incidence, severity, and complications of systemic lupus erythematosus (SLE) are interpreted.…
  • Abstract Number: 1616 • ACR Convergence 2021

    Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley

    Sukesh Sukumaran1, Reshma Patel2 and Deepika Singh3, 1Valley Children's Healthcare, Madera, CA, 2Valley Children's Hospital, Madera, CA, 3Valley Children Healthcare, Madera, CA

    Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
  • Abstract Number: 0596 • ACR Convergence 2021

    Racial Disparities in US Adults with Systemic Lupus Erythematosus: Prevalence, Quality of Life, Comorbidities and Healthcare Costs

    Shannon Grabich1, Cullen Seal2, Robert Ortmann3 and Sandra Sze-jung Wu4, 1Xcenda, Durham, NC, 2Xcenda, Carrollton, TX, 3AstraZeneca, Greenwood, IN, 4AstraZeneca, Wilmington, DE

    Background/Purpose: SLE is a chronic, multisystem autoimmune disease characterized by reoccurring flares and remissions. It is more common among Asian, Black, and Hispanic populations. Racial…
  • Abstract Number: 1680 • ACR Convergence 2021

    Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials

    Grace Wright1, Eduardo Mysler2, Yi-Hsing Chen3, Cassandra Kinch4, Arne Yndestad5, Kenneth Kwok6, Mary Jane Cadatal7, Rebecca Germino8 and Alexis Ogdie9, 1Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, 2Organización Médica de Investigación, Buenos Aires, Argentina, 3Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 4Pfizer Canada ULC, Kirkland, QC, Canada, 5Pfizer Inc, Oslo, Norway, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Manila, Philippines, 8Pfizer Inc, Groton, CT, 9Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: While racial disparities in clinical outcomes for RA patients (pts) receiving bDMARDs or csDMARDs have been described,1 there remains a paucity of data on…
  • Abstract Number: 0598 • ACR Convergence 2021

    Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study

    Adrienne Joseph, Brandon Windsor, Linda Hynan and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Epidemiological studies have shown that discoid lupus erythematosus (DLE) has a higher incidence and prevalence in minorities, particularly Black individuals. Racial differences in clinical…
  • Abstract Number: 1726 • ACR Convergence 2021

    A Pregnancy Planning Quality Score to Assess a Systematic Intervention to Improve Pregnancy Planning for Women with SLE

    Catherine Sims1, Amanda Eudy1, Jayanth Doss1, Lisa Criscione-Schreiber2, Kai Sun2, Rebecca Sadun1, Jennifer Rogers2 and Megan Clowse3, 1Duke University, Durham, NC, 2Duke University School of Medicine, Durham, NC, 3Duke University, Chapel Hill, NC

    Background/Purpose: The safest pregnancies for women with SLE coincide with periods of disease quiescence maintained by pregnancy-compatible medications. In the US, Black women are more…
  • Abstract Number: 0601 • ACR Convergence 2021

    Racial Differences in Medication Beliefs Among SLE Patients

    D Ryan Anderson1, Amanda Eudy2, Megan Clowse3, Rebecca Sadun2, Jennifer Rogers2, Lisa Criscione-Schreiber4, Jayanth Doss2, Corrine Volis5, Theresa Coles2 and Kai Sun2, 1Duke University Hospital, Durham, NC, 2Duke University, Durham, NC, 3Duke University, Chapel Hill, NC, 4Duke University School of Medicine, Durham, NC, 5University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Medication adherence is essential to establishing and maintaining disease remission among SLE patients. Patients’ beliefs about treatment influence engagement and adherence to therapy. We…
  • Abstract Number: 1755 • ACR Convergence 2021

    Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians

    Saira Sheikh1, Maria Naylor2, Becky Lane2, Jennifer Sacks2, Janine Gaiha-Rohrbach2 and Cherie Butts2, 1University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 2Biogen, Cambridge, MA

    Background/Purpose: Systemic lupus erythematosus disproportionately affects Black/African American (AA) and Latino/a populations.1 Challenges to engage and include these populations in clinical trials (CTs) can be…
  • Abstract Number: 0604 • ACR Convergence 2021

    Disparities in Burden of Disease in Patients with RA Across Racial and Ethnic Groups

    Jacqueline O’Brien1, Sang Hee Park2, Taylor Blachley1, Maya Marchese1, Nicole Middaugh1, Xue Han2, Keith Wittstock2 and Leslie Harrold1, 1CorEvitas, LLC, Waltham, MA, 2Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Prior research has shown that differences exist in disease activity and clinical outcomes for RA across racial and ethnic groups in the US.1 This…
  • Abstract Number: 1780 • ACR Convergence 2021

    Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis

    Sabahath Jaleel1, Yael Ross1 and Marina Magrey2, 1Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, 2Case Western Reserve Universtiy at MetroHealth Medical Center, Cleveland, OH

    Background/Purpose: Racial heterogeneity of the US population makes it imperative to study the racial differences in clinical characteristics, medication use and co-morbidities of PsA patients…
  • Abstract Number: 0608 • ACR Convergence 2021

    Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients

    Valerie Umaefulam1, Terri-Lynn Fox1, Glen Hazlewood1, Nick Bansback2, Claire Barber1 and Cheryl Barnabe1, 1University of Calgary, Calgary, AB, Canada, 2University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Patient decision aids (PtDA) can enable shared decision-making between patients and healthcare providers. We have previously developed a PtDA for first-line methotrexate-based treatment options…
  • Abstract Number: 1839 • ACR Convergence 2021

    Hispanic Patients with Systemic Sclerosis Have More Severe Disease and Higher Mortality: A Longitudinal Cohort Study

    Bochra Jandali1, Marka Lyons2, Julio Charles2, Maureen Mayes3 and Shervin Assassi1, 1University of Texas McGovern Medical School at Houston, Houston, TX, 2Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, 3Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX

    Background/Purpose: Systemic sclerosis (SSc) shows disparities in incidence, disease manifestations, and prognosis in different ethnic groups. The data regarding disease characteristics and outcomes in Hispanic…
  • Abstract Number: 0610 • ACR Convergence 2021

    Evaluating Patient No Show Rates to Rheumatology Appointments Across a Regional Healthcare System

    Osman Bhatty1, Rebecca Schorr2, Tarun Sharma1 and Mary Chester Wasko1, 1Allegheny Health Network, Pittsburgh, PA, 2Highmark Health, Pittsburgh, PA

    Background/Purpose: No-show visits in various clinical settings are costly to providers and to health care systems, potentially representing between 3-14% of a clinic’s yearly income.…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology